查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008489

類澱粉沉積症治療市場：依治療方法、給藥途徑、藥物類別、類澱粉沉積症類型及最終用戶分類－2026年至2032年全球市場預測

Amyloidosis Treatment Market by Treatment Type, Route Of Administration, Drug Class, Amyloidosis Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年類澱粉沉積症治療市場價值為 61.3 億美元，預計到 2026 年將成長至 65.9 億美元，複合年成長率為 7.56%，到 ​​2032 年將達到 102.1 億美元。

主要市場統計數據
基準年 2025 61.3億美元
預計年份：2026年 65.9億美元
預測年份 2032 102.1億美元
複合年成長率 (%) 7.56%

全面概述了目前類澱粉沉積症治療領域的最新診斷進展、擴展的治療方法和不斷發展的護理路徑。

類澱粉沉積症曾是一種罕見且易誤診的疾病，如今已發展成為一個治療領域，其特點是診斷技術的快速進步和標靶治療的蓬勃發展。近年來，臨床醫生和研究人員受益於生物標記檢測、影像學技術以及透過多學科協作改進的診療路徑，從而實現了更早期的檢測和更精準的表現型分析。這些臨床進展為更有效地實施治療性介入和更詳細地追蹤患者預後提供了契機。

標靶分子療法、早期檢測和不斷發展的醫療保健服務模式如何重新定義類澱粉沉積症的臨床和商業性重點。

過去十年，類澱粉沉積症的治療格局發生了翻天覆地的變化，這主要得益於標靶分子療法的出現、診斷演算法的改進以及臨床實踐模式的重塑。 TTR 抑制劑和穩定器的出現重新定義了 ATTR 亞型澱粉樣變性的治療目標，為直接調控潛在致病級聯反應提供了治療方法。同時，AL類澱粉沉積症的單株抗體療法改變了標準的誘導治療方案，並為先前對標準治療無效的患者拓展了治療選擇。

評估 2025 年美國關稅變化對類澱粉沉積症變性治療中藥品供應鏈、籌資策略和患者取得途徑的多方面影響。

2025年實施的貿易政策發展和關稅調整進一步增加了美國醫藥和生物製藥供應鏈相關人員的營運複雜性。累積關稅措施，特別是那些影響關鍵進口商品（例如活性藥物成分、特種化學品和某些成品生物製藥）的措施，正在加劇本已採用準時生產模式、庫存極低的供應鏈的成本壓力。不斷上漲的投入成本正推高製造商的成本結構，迫使他們重新評估其分銷、採購和定價策略。

將治療方法、分子分類、給藥途徑、臨床環境和疾病亞型與商業性和臨床決策聯繫起來的細分市場主導洞察。

對市場細分的詳細分析揭示了臨床需求、商業性機會和營運風險的交匯點。根據治療類型，整體情況包括藥物治療、幹細胞移植和支持治療。藥物治療方案進一步細分為烷化劑、免疫調節劑、單株抗體、蛋白酶體抑制劑、TTR 沉默劑和 TTR 穩定劑。這些分類的例子包括Melphalan（烷化劑）、來那度胺（免疫調節劑）、Lenalidomide（單株抗體）、Daratumumab佐米、Carfilzomib和Bortezomib（蛋白酶體抑制劑）、Ixazomib和帕替西蘭（TTR 沉默劑）以及阿可拉米迪和他法米迪（TTR 穩定劑）。根據給藥途徑，治療方法可採用靜脈注射、口服和皮下注射，每種途徑對物流、用藥依從性和臨床實施環境的影響各不相同。

影響全球類澱粉沉積症變性治療區域診斷、報銷途徑、供應鏈韌性和部署計畫的區域差異。

區域趨勢持續影響醫療服務的可近性、投資和臨床實踐，因此需要採取因地制宜的策略。在美洲，高度專業化的醫療中心集中分佈，且歷來擁有雄厚的創新資金籌措支持，從而促進了新療法和診斷技術的快速應用。然而，公立和私立醫療體系之間不同的支付政策導致病患就醫和報銷時間存在差異。相較之下，歐洲、中東和非洲地區的情況則更為複雜，實行單一支付系統的地區能夠提供更為標準化的就醫途徑，而其他市場則由於基礎設施的限制，在推廣高成本治療方法進展緩慢。

大型製藥企業的規模、生物技術創新、診斷領域的合作以及生產策略的相互作用，如何決定它們在類澱粉沉積症領域的競爭地位？

類澱粉沉積症領域的競爭格局由大型製藥企業、專業生物技術公司、契約製造和診斷公司組成，它們共同努力，為創新和藥物可及性創造了充滿活力的環境。擁有完善商業基礎設施的成熟製藥公司在擴大已通過核准治療方法的覆蓋範圍和談判複雜的醫保報銷協議方面發揮著至關重要的作用，而靈活的生物技術公司則往往在下一代抑製劑、穩定劑和靶向生技藥品的早期創新方面發揮著主導作用。

為類澱粉沉積症領域的製造商、支付方和醫療保健提供者制定可操作的策略重點，以改善可及性、確保供應彈性並展現永續的臨床價值。

產業領導者應採取多管齊下的策略，在不斷變化的政策和供應挑戰下，充分發揮臨床價值並維持藥物可及性。優先投資診斷基礎設施和臨床醫生教育至關重要，這有助於透過促進早期檢測和準確的亞型鑑定來提高疾病修正治療的臨床效用。同時，應制定循證方案，將隨機對照試驗數據和可操作的真實世界數據相結合，以支持與支付方開展有效的價值對話，並降低處方藥在不同報銷環境下的風險。

結合臨床專家見解、公開監管記錄和系統文獻綜述的穩健混合方法研究途徑，可以得出基於證據的結論。

本分析整合了第一手和第二手研究方法，旨在全面展現臨床、商業性和營運趨勢。第一手研究包括對關鍵意見領袖（KOL）進行結構化訪談，訪談對象涵蓋血液科醫生、循環系統科醫生、神經科醫生、專科診所主任和採購負責人，以及與行業高管進行對話，以深入了解產品線開發和商業化策略的背景資訊。第二手研究包括對同行評審的臨床文獻、監管核准和適應症更新、臨床試驗註冊數據以及上市公司資訊披露進行系統性回顧，並輔以對最新診斷指南和支付方政策公告的檢驗。

概述了將診斷技術進步、治療方法多樣化和創新與對患者產生更廣泛影響所需的策略措施。

總之，類澱粉沉積症治療領域正進入一個診斷技術進步與治療方法多樣化相融合的新階段，為改善患者預後和實現策略性商業性成長創造了切實機會。臨床醫生現在可以使用更多種類的緩解疾病藥物和輔助療法，醫療保健系統也正在調整其服務模式以適應慢性病管理路徑。貿易政策的變化和供應鏈壓力凸顯了製定具有韌性的籌資策略的必要性，而區域差異則要求制定因地制宜的市場准入和循證實踐計劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：類澱粉沉積症治療市場（依治療方法分類）

  • 藥物治療
    • 烷化劑
    • 免疫調節劑
    • 單株抗體
    • 蛋白酶體抑制劑
      • Bortezomib
      • Carfilzomib
      • 伊沙佐米
    • TTR消音器
      • 伊諾特森
      • 糕點師
    • TTR穩定器
      • 阿科拉米迪斯
      • 塔法米迪斯
  • 幹細胞移植
  • 支持性護理

第9章類澱粉沉積症治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：類澱粉沉積症治療市場：依藥物類別分類

  • 烷化劑
  • 免疫調節劑
  • 單株抗體
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • 伊沙佐米
  • TTR消音器
    • 伊諾特森
    • 糕點師
  • TTR穩定器
    • 阿科拉米迪斯
    • 塔法米迪斯

第11章類澱粉沉積症治療市場（依類澱粉沉積症類型分類）

  • AA
  • AL
  • 遺傳性ATTR
  • 野生型 ATTR

第12章類澱粉沉積症治療市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第13章類澱粉沉積症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章類澱粉沉積症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章類澱粉沉積症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國類澱粉沉積症治療市場

第17章：中國類澱粉沉積症治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbvie, Inc.
  • Acrotech Biopharma, Inc
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals Inc.
  • Arcturus Therapeutics, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Attralus, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Corino Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc
  • Merck & Co., Inc.
  • Neurimmune AG
  • Oncopeptides AB
  • Pfizer Inc.
  • Proclara Biosciences Inc.
  • Prothena Corporation PLC
  • Regeneron Pharmaceuticals Inc.
  • SOM INNOVATION BIOTECH, SA,
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market was valued at USD 6.13 billion in 2025 and is projected to grow to USD 6.59 billion in 2026, with a CAGR of 7.56%, reaching USD 10.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.13 billion
Estimated Year [2026] USD 6.59 billion
Forecast Year [2032] USD 10.21 billion
CAGR (%) 7.56%

Comprehensive orientation to recent diagnostic precision, therapeutic expansion, and evolving care pathways shaping amyloidosis management today

Amyloidosis has evolved from a rare, often misdiagnosed condition into a therapeutic area marked by rapid diagnostic refinement and a proliferation of targeted treatments. In recent years, clinicians and researchers have benefited from improved biomarker assays, imaging modalities, and multidisciplinary care pathways that together enable earlier detection and more precise phenotyping. These clinical advances create opportunities for therapeutic interventions to be deployed more effectively and for patient outcomes to be tracked with greater granularity.

Concurrently, the treatment toolkit has expanded across multiple modalities. Pharmacological treatments encompass a range of approaches from classic alkylating agents to next-generation TTR silencers and stabilizers, while autologous stem cell transplantation remains a curative-intent option for eligible patients. Supportive therapies continue to play a pivotal role in symptom control and quality-of-life enhancement, particularly as disease-modifying agents extend survival and shift focus toward long-term management. As a result, care delivery models are adapting to balance specialist-driven hospital care, outpatient specialty clinics, and increasing home-based services.

This introduction frames the broader executive summary by emphasizing the interplay between diagnostics, therapeutic innovation, and care delivery. It sets the stage for deeper analysis of market dynamics, regulatory pathways, and stakeholder strategies that follow, while underscoring the importance of integrating clinical evidence with commercial planning to capitalize on emerging opportunities and to address persistent access challenges.

How targeted molecular therapies, earlier detection, and evolving care delivery models are collectively redefining clinical and commercial priorities in amyloidosis

Over the past decade, the amyloidosis landscape has experienced transformative shifts driven by targeted molecular therapies, improved diagnostic algorithms, and a recalibration of clinical practice patterns. The arrival of TTR silencers and stabilizers has reframed treatment goals for ATTR subtypes, bringing therapies that directly modulate the underlying pathogenic cascade. At the same time, monoclonal antibody approaches for AL amyloidosis have changed standard induction regimens and expanded options for patients who were previously refractory to conventional regimens.

Diagnostic progress, including more sensitive cardiac imaging and refined biomarkers, has enabled clinicians to identify amyloid subtypes earlier and to stratify patients by risk with greater confidence. This earlier detection translates into heightened demand for interventions that can alter disease trajectory rather than simply palliate symptoms, and it increases the importance of care coordination across cardiology, neurology, hematology, and specialized clinics. Parallel to therapeutic and diagnostic advances, payer and regulatory environments have adapted by creating more robust pathways for accelerated approvals and conditional access programs, although reimbursement negotiations remain complex in many jurisdictions.

Finally, health systems and providers are adapting delivery models to accommodate chronic management needs. There is a visible shift toward integrating home-based infusion and monitoring where clinically appropriate, and toward specialty clinic hubs that concentrate expertise and facilitate rapid initiation of complex therapies. These systemic shifts are collectively reshaping investment priorities, R&D focus, and commercial strategies across the ecosystem.

Assessing the multifaceted effects of 2025 United States tariff changes on pharmaceutical supply chains, procurement strategies, and patient access in amyloidosis care

Trade policy developments and tariff adjustments instituted in 2025 have introduced another layer of complexity for stakeholders operating in the United States pharmaceutical and biologics supply chains. Cumulative tariff measures, particularly those affecting key import categories such as active pharmaceutical ingredients, specialty chemicals, and certain finished biologics components, have increased the cost pressure on supply chains that are already operating with lean inventories and just-in-time manufacturing approaches. These elevated input costs exert upward pressure on manufacturers' cost structures and force reassessment of distribution, procurement, and pricing strategies.

Beyond direct cost impacts, tariffs can induce shifts in sourcing decisions and contractual terms. Companies may accelerate nearshoring or diversify supplier bases to mitigate exposure to tariff volatility, while contract manufacturers reassess capacity commitments and lead times. In tandem, payers and integrated delivery networks may respond to rising acquisition costs by intensifying value-based contracting discussions, demanding clearer real-world evidence of clinical benefit and long-term outcomes. For smaller biotech firms, the financial strain of increased input costs and elongated supply chains can slow clinical development timelines and complicate commercialization plans.

Clinicians and patients can also experience indirect effects: sporadic supply disruptions or pricing pressures may constrain access to specialized formulations or result in prioritization schemes by providers. In response, resilient companies are investing in supply chain visibility tools, multi-sourcing agreements, and strategic inventory buffers to preserve continuity of care while maintaining competitive positioning. Regulatory engagement and public-private dialogue remain important levers to ensure essential therapies maintain stable availability despite broader trade policy shifts.

Segment-driven insights that link therapeutic modality, molecular class, administration route, care setting, and disease subtype to commercial and clinical decision-making

A granular view of segmentation illuminates where clinical needs intersect with commercial opportunity and operational risk. Based on treatment type, the therapeutic landscape encompasses pharmacological treatment, stem cell transplantation, and supportive therapy, with pharmacological options further categorized into alkylating agents, immunomodulators, monoclonal antibodies, proteasome inhibitors, TTR silencers, and TTR stabilizers; examples within these classes include melphalan among alkylating agents, lenalidomide among immunomodulators, daratumumab within monoclonal antibodies, bortezomib, carfilzomib and ixazomib among proteasome inhibitors, and inotersen and patisiran representing TTR silencers while acoramidis and tafamidis exemplify TTR stabilizers. Based on route of administration, therapies span intravenous, oral, and subcutaneous delivery, each of which imposes distinct logistical, adherence, and site-of-care implications for deployment.

Examining end users, care is delivered across home care settings, hospitals, and specialty clinics, and each channel shapes product design, patient support needs, and reimbursement pathways. Based on drug class segmentation, the overlap between pharmacological taxonomy and molecular mechanism highlights where therapeutic substitution or combination strategies are clinically plausible. Finally, by amyloidosis type including AA, AL, hereditary ATTR, and wild-type ATTR, clinical presentation and progression differ markedly, which in turn influence the suitability of transplantation, the selection of disease-modifying agents, and the emphasis on supportive care.

Taken together, this segmentation matrix supports targeted product development, precision commercial approaches, and differentiated patient support models. It also informs clinical trial design by clarifying endpoints and subgroup stratification that resonate with regulatory reviewers and payer assessments.

Nuanced regional considerations affecting diagnostics, reimbursement pathways, supply chain resilience, and adoption timelines across global amyloidosis care geographies

Regional dynamics continue to shape access, investment, and clinical practice in ways that require tailored strategies. In the Americas, concentrated centers of excellence and a historically aggressive innovation funding environment support rapid adoption of novel therapeutics and diagnostic technologies, but divergent payer policies across public and private systems create variability in patient access and reimbursement timelines. In contrast, the Europe, Middle East & Africa region presents a heterogeneous mosaic where single-payer jurisdictions may enable more standardized adoption pathways while other markets face infrastructural constraints that delay diffusion of high-cost therapies.

Asia-Pacific markets exhibit a mix of rapid biopharmaceutical manufacturing expansion and diverse regulatory approaches; several countries within the region are building local production capabilities and regulatory frameworks that aim to both attract clinical development activity and lower dependence on external supply chains. Across regions, variations in diagnostic capacity, specialist availability, and local treatment guidelines influence how rapidly new modalities move from approval to routine care. In low-resource settings, supportive care and symptom management often remain the immediate priorities, while high-resource systems increasingly emphasize long-term disease modification and integrated care models.

Strategic entrants must therefore align commercialization, medical affairs, and supply strategies to regional nuances. This includes adapting value demonstration dossiers to local evidence requirements, investing in clinician education where diagnostic literacy remains nascent, and establishing manufacturing or sourcing partnerships to reduce tariff and logistics exposure while accelerating time to patient.

How the interplay between big pharma scale, biotech innovation, diagnostics partnerships, and manufacturing strategies is determining competitive positioning in amyloidosis

Competitive activity across the amyloidosis space reflects a mix of large pharmaceutical companies, specialized biotech innovators, contract manufacturing organizations, and diagnostics firms that together shape the innovation and access landscape. Established pharmaceutical companies with broad commercial infrastructures play a pivotal role in scaling approved therapies and negotiating complex reimbursement arrangements, while nimble biotech firms tend to drive early-stage innovation in next-generation silencers, stabilizers, and targeted biologics.

Strategic partnerships and licensing agreements have become central to accelerating clinical development and market entry. Collaborations between therapy developers and diagnostics providers are increasingly important to ensure accurate patient identification and to support companion diagnostic strategies that underpin value-based contracting. Contract manufacturing organizations and regional producers also play a critical role by offering capacity to mitigate tariff exposure and to enable localized supply chains that reduce lead times for critical therapies.

Investors and potential partners should monitor pipeline progression, regulatory milestones, and evidence-generation strategies that differentiate products in terms of clinical benefit and real-world applicability. Companies that demonstrate robust post-approval evidence collection, invest in patient support services, and proactively engage payers and clinician networks are better positioned to translate clinical promise into sustainable adoption across diverse care settings.

Actionable strategic priorities for manufacturers, payers, and providers to enhance access, ensure supply resilience, and demonstrate sustained clinical value in amyloidosis

Industry leaders should adopt a multi-pronged approach to capture clinical value and to sustain access amidst evolving policy and supply challenges. Prioritize investments in diagnostic infrastructure and clinician education to drive earlier detection and appropriate subtype assignment, thereby increasing the clinical utility of disease-modifying therapies. Concurrently, design evidence-generation plans that combine randomized data with pragmatic real-world evidence to support robust value conversations with payers and to de-risk formulary inclusion across different reimbursement environments.

Reinforce supply chain resilience through supplier diversification, selective nearshoring, and strategic inventory buffers for critical inputs. Negotiate flexible contractual terms with suppliers and logistics partners to accommodate tariff volatility and to preserve continuity of care. Align product development with route-of-administration preferences for targeted patient cohorts, recognizing that oral and subcutaneous formulations can expand home-based care opportunities while intravenous regimens often require hospital or clinic resources.

Finally, cultivate partnerships across the ecosystem-including diagnostics providers, specialty clinics, and patient advocacy groups-to build comprehensive care pathways that improve adherence, monitor outcomes, and support long-term disease management. Embrace outcome-based contracting where feasible, and invest in digital tools that enable remote monitoring and patient engagement, thereby strengthening the real-world case for therapeutic value and enabling more predictable reimbursement conversations.

Robust mixed-methods research approach combining clinical expert insights, public regulatory records, and systematic literature review to ensure evidence-driven conclusions

This analysis synthesizes primary and secondary research methods to deliver a balanced view of clinical, commercial, and operational dynamics. Primary research comprised structured interviews with key opinion leaders including hematologists, cardiologists, neurologists, specialty clinic directors, and procurement executives, combined with dialogues with industry executives to contextualize pipeline developments and commercialization strategies. Secondary research involved systematic review of peer-reviewed clinical literature, regulatory approvals and label updates, clinical trial registries, and public company disclosures, augmented by an examination of diagnostic guideline updates and payer policy announcements.

Data triangulation ensured that clinical findings align with observed commercial behaviors and supply chain realities. Qualitative insights from expert interviews were cross-validated with published trial outcomes and regulatory documentation to mitigate bias and to refine interpretations. Analytical techniques included thematic synthesis for qualitative inputs and comparative trend mapping to highlight regional and segment-level differences. The methodology prioritized transparency in assumptions and explicitly excluded speculative market sizing or forecasting to maintain focus on actionable intelligence and evidence-based recommendations.

Concluding synthesis of diagnostic advances, therapeutic diversification, and strategic actions required to translate innovation into broader patient impact

In conclusion, the amyloidosis landscape is entering a phase where diagnostic sophistication and therapeutic diversity converge to create tangible opportunities for improved patient outcomes and strategic commercial growth. Clinicians now have access to a wider array of disease-modifying agents and supportive strategies, and health systems are recalibrating care delivery to accommodate chronic management pathways. Trade policy shifts and supply chain pressures underscore the need for resilient sourcing strategies, while regional heterogeneity demands tailored market entry and evidence-generation plans.

For stakeholders across the ecosystem, the path forward involves aligning clinical innovation with pragmatic access mechanisms and operational preparedness. By investing in diagnostics, forging strategic partnerships, and collecting meaningful real-world evidence, organizations can bridge the gap between clinical potential and widespread patient benefit. The recommendations contained herein provide a roadmap for navigating the evolving therapeutic, regulatory, and commercial environment surrounding amyloidosis treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyloidosis Treatment Market, by Treatment Type

  • 8.1. Pharmacological Treatment
    • 8.1.1. Alkylating Agents
    • 8.1.2. Immunomodulators
    • 8.1.3. Monoclonal Antibodies
    • 8.1.4. Proteasome Inhibitors
      • 8.1.4.1. Bortezomib
      • 8.1.4.2. Carfilzomib
      • 8.1.4.3. Ixazomib
    • 8.1.5. TTR Silencers
      • 8.1.5.1. Inotersen
      • 8.1.5.2. Patisiran
    • 8.1.6. TTR Stabilizers
      • 8.1.6.1. Acoramidis
      • 8.1.6.2. Tafamidis
  • 8.2. Stem Cell Transplantation
  • 8.3. Supportive Therapy

9. Amyloidosis Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Amyloidosis Treatment Market, by Drug Class

  • 10.1. Alkylating Agents
  • 10.2. Immunomodulators
  • 10.3. Monoclonal Antibodies
  • 10.4. Proteasome Inhibitors
    • 10.4.1. Bortezomib
    • 10.4.2. Carfilzomib
    • 10.4.3. Ixazomib
  • 10.5. TTR Silencers
    • 10.5.1. Inotersen
    • 10.5.2. Patisiran
  • 10.6. TTR Stabilizers
    • 10.6.1. Acoramidis
    • 10.6.2. Tafamidis

11. Amyloidosis Treatment Market, by Amyloidosis Type

  • 11.1. AA
  • 11.2. AL
  • 11.3. Hereditary ATTR
  • 11.4. Wild-Type ATTR

12. Amyloidosis Treatment Market, by End User

  • 12.1. Home Care
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Amyloidosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyloidosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyloidosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Amyloidosis Treatment Market

17. China Amyloidosis Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbvie, Inc.
  • 18.6. Acrotech Biopharma, Inc
  • 18.7. Alexion Pharmaceuticals
  • 18.8. Alnylam Pharmaceuticals Inc.
  • 18.9. Arcturus Therapeutics, Inc.
  • 18.10. Astellas Pharma, Inc.
  • 18.11. AstraZeneca PLC
  • 18.12. Attralus, Inc.
  • 18.13. BridgeBio Pharma, Inc.
  • 18.14. Bristol-Myers Squibb Company
  • 18.15. Corino Therapeutics, Inc.
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Ionis Pharmaceuticals, Inc.
  • 18.18. Johnson & Johnson Services Inc
  • 18.19. Merck & Co., Inc.
  • 18.20. Neurimmune AG
  • 18.21. Oncopeptides AB
  • 18.22. Pfizer Inc.
  • 18.23. Proclara Biosciences Inc.
  • 18.24. Prothena Corporation PLC
  • 18.25. Regeneron Pharmaceuticals Inc.
  • 18.26. SOM INNOVATION BIOTECH, SA,
  • 18.27. Sorrento Therapeutics, Inc.
  • 18.28. Spectrum Pharmaceuticals, Inc.
  • 18.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY INOTERSEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PATISIRAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ACORAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TAFAMIDIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY AL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HEREDITARY ATTR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY WILD-TYPE ATTR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 253. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 292. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 305. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY AMYLOIDOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. NATO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR SILENCERS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TTR STABILIZERS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED S